



Tokyo, February 6, 2019

FOR IMMEDIATE RELEASE

TRANSFER OF RIGHTS TO protease inhibitor FUTHAN® for injection

Today, Torii Pharmaceutical Co., Ltd (Torii) (TSE:4551) has announced that Nichi-Iko Pharmaceutical Co., Ltd. (Nichi-Iko) (TSE:4541) will acquire the marketing authorization and take over the marketing activities for protease inhibitor FUTHAN ® 10mg and 50mg for injection ("FUTHAN") from Torii on April 1, 2019.

1. Rationale of the transfer

FUTHAN has long been used for treatments for many patients as one of main products in renal disease and hemodialysis of Torii since 1986. Torii intends to focus on extending and maximizing values of the new products and transfer FUTHAN, based on the drastic reform of the drug price system.

On the other hand, Nichi-Iko hopes to continue contributing to patients and their family, and to enhance the corporate presence in blood purification area.

So, Torii and Nichi-Iko have entered an agreement.

2. Overview of the transfer

Products			FUTHAN ® 10mg for injection FUTHAN ® 50mg for injection
Indication	FUTHAN 10mg	FUTHAN 50mg	Improvement of acute symptoms of pancreatitis
			Disseminated Intravascular Coagulation (DIC)
			Prevention of coagulation of perfused blood during extravascular circulation of patients with bleeding lesions or bleeding tendencies
Launch			FUTHAN 10mg : October, 1986 FUTHAN 50mg : June, 1989
Sales			1.1billion yen in 2018

Nichi-Iko will be responsible for not only providing and gathering FUTHAN's information but also supplying FUTHAN stably from April 1, 2019.

Even then the transfer day, Torii will product FUTHAN until Nichi-Iko prepares its production line.

Torii will receive a consideration from Nichi-Iko. Nichi-Iko and Torii don't disclose the amount of consideration because of business circumstances.

### 3. Overview of Nichi-Iko

(1) Name	Nichi-Iko Pharmaceutical Co., Ltd.	
(2) Address	(HQ)1-6-21 Sogawa, Toyama City, Toyama Prefecture, Japan (Tokyo HQ)5-4 Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo, Japan	
(3) Representative	President and CEO: Yuichi Tamura	
(4) Business	Manufacturing, sales, distribution, export, import and related activities for various types of pharmaceuticals	
(5) Capital	19,976 million yen	
(6) Foundation	July 15 1965	
(7) Total Equity	100,646 million yen (As of September 30,2018)	
(8) Total Assets	281,722 million yen (As of September 30,2018) )	
(9) Principal shareholders (As of September 30,2018)	TAMURA Co., Ltd.	7.61%
	Hokuriku Bank, Ltd.	4.74%
	Taku Co., Ltd.	3.56%
	Yuichi Tamura	3.00%
	The Master Trust Bank of Japan, Ltd. (Trust Account)	2.37%
	Japan Trustee Services Bank, Ltd. (Trust Account)	2.23%
	Nipro Corporation	2.21%
	Japan Trustee Services Bank, Ltd. No.9	2.02%
	Japan Trustee Services Bank, Ltd. No.5	1.66%
	Nichi-Iko Employee Shareholding Association	1.41%
(10) Relationship with Torii	Capital	None
	Personnel	None
	Business	None
	Related party	None

### 4. Schedule

(1)The date of the board of directors	February 6, 2019
(2)The date of agreements	February 6, 2019
(3)The date of transfer	April 1, 2019

5. Impact on Financial Performance

Torii's forecasts in the fiscal year ending December 2019, which is announced today, already includes this transfer and consideration from Nichi-Iko.

Contact for Torii Pharmaceutical Co., Ltd.:  
Corporate Planning Department  
(Public Relations)  
Torii Pharmaceutical Co., Ltd.  
Tokyo: +81-3-3231-6814